Among the miR-361 target genes identified in this study, MEF2D is involved in tumor promotion in pancreatic cancer [20], hepatocellular carcinoma [33], osteosarcoma [34], lung cancer [35], gastric cancer [36], colorectal cancer [37], and osteosarcoma [38]. This evidence concerns the gene MEF2D and familial pancreatic carcinoma.